| Literature DB >> 34032329 |
Veselin Nasufović1, Florian Küllmer1, Johanna Bößneck1, Hans-Martin Dahse2, Helmar Görls3, Peter Bellstedt4, Pierre Stallforth2, Hans-Dieter Arndt1.
Abstract
The first total synthesis of the actin-stabilizing marine natural product geodiamolide H was achieved. Solid-phase based peptide assembly paired with scalable stereoselective syntheses of polyketide building blocks and an optimized esterification set the stage for investigating the key ring-closing metathesis. Geodiamolide H and synthetic analogues were characterized for their toxicity and for antiproliferative effects in cellulo, by characterising actin polymerization induction in vitro, and by docking on the F-actin target and property computation in silico, for a better understanding of structure-activity relationships (SAR). A non-natural analogue of geodiamolide H was discovered to be most potent in the series, suggesting significant potential for tool compound design.Entities:
Keywords: Actin; antitumor agents; natural products; structure-activity relationship; total synthesis
Mesh:
Substances:
Year: 2021 PMID: 34032329 PMCID: PMC8453818 DOI: 10.1002/chem.202100989
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236
Figure 1Cytotoxic F‐actin‐binding natural products and retrosynthetic simplification of 19‐membered cyclodepsipeptides. Key positions of the geodiamolide H structure are indicated. Complete numbering can be found in the Supporting Information (Table S1).
Scheme 1Diastereoselective synthesis of (2S,4R)‐4‐methylhex‐5‐en‐2‐ol (11). Conditions and reagents: (a) Allylmagnesium bromide (1.3 equiv.), Et2O, −78 °C, 2 h, 84 %; (b) NaH (3.0 equiv.), TIPS‐Cl (1.2 equiv.), THF, 0 °C to 25 °C, 16 h, 78 %; (c) NMO (1.5 equiv.), 2,6‐Lutidine (2 equiv.), OsO4 (3 mol %), acetone/water (c=0.1 M), 25 °C, 3 h, then PhI(OAc)2 (1.5 equiv.), 3 h, 83 %; (d) N‐Hydroxysuccinimide (1.05 equiv.), 0 °C then PhI(OAc)2 (1.05 equiv.), MeCN, −5 °C, 1 h, 73 %; (e) Seebach's oxazolidinone (1.1 equiv.), n‐BuLi (1.1 equiv., 2.35 M), THF, −78 °C, 10 min, then active ester from d (1.0 equiv.) in THF added, −78 °C to 25 °C, 16 h, 82 %; (f) LDA (1.5 equiv.), THF, −78 °C 1 h, then MeI (12 equiv.), −40 °C, 4 h, 89 %; (g) LiBH4 (1.1 equiv.), H2O (1.1 equiv.), THF, 0 °C, 3 h, 98 %; (h) SO3/Py (2.0 equiv.), DMSO (9 equiv.), DIPEA (4.0 equiv.), DCM ‐30 °C to 25 °C, 5 h, 94 %; (i) 1i. Ph3PMeBr (2.2 equiv.), THF, −78 °C, BuLi (2.0 equiv.), 1 h then 30 min at 0 °C, 2i. aldehyde from h (2.0 equiv.), −78 °C, 1 h, 92 %, (j) TBAF (2.2 equiv.), THF, 25 °C, 6 h, 96 %.
Figure 2The solid‐state structure of key intermediate 16 determined by single‐crystal X‐ray diffraction.
Scheme 2Synthesis of N‐Me‐Tyrosine derivatives. Conditions and reagents: (a) I2 in aq. NH3 30 % (1.0 equiv.), 0 °C, 3 h, 83 % (only for synthesis of 8); (b) Boc2O (1.1 equiv.), TEA (1.5 equiv.), 1,4‐dioxane/H2O (1 : 1), 0 °C, 8 h, quant; (c) 1c. DCE (1.05 equiv.) 0 °C, 30 min, DCM then TIPS‐Cl (1.1 equiv.), 2 h, 2c. Imidazole (2.0 equiv.), DMAP (0.2 equiv.), TIPS‐Cl (1.1 equiv.), 16 h, 25 °C; 3c. K2CO3 (2.0 equiv.), MeOH/THF/H2O, 30 min, 25 °C; (d) NaH (2.1 equiv.), MeI (8.0 equiv.), THF, 0 °C to 25 °C, 16 h; (e) 20 % TFA/DCM, 0 °C, 4 h, (f) Fmoc‐OSu, 1,4‐dioxane/H2O, NaHCO3, 0 °C to 25 °C, 16 h; for detailed procedures see Supporting Information.
Screening of esterification conditions and synthesis of linear ester‐dienes.[a]
|
| ||||||
|---|---|---|---|---|---|---|
|
Entry |
Peptide |
Alcohol (equiv.) |
Conditions (equiv.) |
Product |
Yield | |
|
1 |
21 |
12 |
|
EDCI |
25 |
22 % |
|
2 |
21 |
12 |
|
TFFH |
25 |
|
|
3 |
21 |
12 |
|
Ghosez's reag. |
25 |
|
|
4 |
21 |
12 |
|
MSNT |
25 |
<10 % |
|
5 |
21 |
12 |
|
Yamaguchi reag. |
25 |
46 % |
|
6 |
21 |
12 |
|
Shiina's reagent |
25 |
82 % |
|
7 |
21 |
11 |
|
Shiina's reagent |
24 |
74 % |
|
8 |
22 |
11 |
|
Shiina's reagent |
26 |
58 % |
|
9 |
22 |
12 |
|
Shiina's reagent |
27 |
77 % |
[a] Conditions and reagents: (a) EDCI, 12, DMAP (0.2 equiv.), DCM 0 °C to 25 °C, 16 h; (b) TFFH, Et3N (6.0 equiv.), DCM, 0 °C, 30 min at 25 °C then 12, DMAP (0.2 equiv.), DCM 25 °C, 16 h; (c) Ghosez's reagent, DCM, 0 °C, 1 h, removal of volatiles, then: 12, DMAP (0.2 equiv.), DCM 0 °C to 25 °C, 13 h; (d) MSNT, 1‐Methylimidazole (2.0 equiv.), 12, DCM, 0 °C to 25 °C, 16 h; (e) Yamaguchi reagent, THF, Et3N (2.0 equiv.), 0 °C to 25 °C, 1 h, removal of volatiles, then: 12, DMAP (1.2 equiv), toluene, 70 °C, 13 h; (f) Shiina's reagent, DIPEA (2.0 equiv), DCM, 25 °C, 30 min, then 11 or 12, DMAP (1.0 equiv), DCM, reflux, 16 h. [b] n.c.= no conversion.
Macrocyclization and completion of synthesis.[a]
|
| |||||
|---|---|---|---|---|---|
|
Entry |
Diene |
X |
R1 |
RCM products (yield) |
Final products (yield) |
|
|
|
I |
Me |
|
|
|
|
|
I |
H |
|
|
|
|
|
H |
Me |
|
|
|
|
|
H |
H |
|
|
[a] Conditions and reagents: (a) Grubbs catalyst 2nd generation 28 (7 mol % for 25 and 27, 35 mol % for 24 and 26), toluene, 0.1 mM concentration, reflux with constant purge of Ar, 2 h (for 25 and 27), 4 h (for 24 and 26); (b) 70 % HF/Pyridine, THF, 25 °C, 24 h, N2, prep. HPLC. [b] Combined, roughly equimolar E/Z‐ratio as estimated by 1H NMR spectroscopy. [c] Isolated yield after purification.
Scheme 3Competitive pathways of product formation during ring‐closing metathesis.
Figure 3In vitro actin polymerization induced by cyclodepsipeptides. Geodiamolides and jasplakinolide (each 20 μM) were incubated with pyrene‐labelled actin (5 μM) under low salt non‐polymerizing conditions. k: slopes of linearly fitted curves given in RFU/s; see Supporting Information for details.
Activity of geodiamolide H and analogues in cellulo and on target:[a]
|
Entry |
Compound |
R |
X |
E/Z |
Cytotoxicity[ii] |
Antiproliferative activity[ii] |
Activity on target |
| ||
|
|
|
|
|
|
HeLa CC50[μM] |
HUVEC GI50[μM] |
K‐562 GI50[μM] |
relative slope (RFU/s)a |
Krel [i] | |
|
|
|
|
|
|
0.08 (±0.01) |
0.010 (±0.002) |
2.4 (±1.0) |
2.37 |
1.00 | |
|
|
|
CH3 |
I |
|
0.4 (±0.01) |
0.27 (±0.08) |
8.2 (±3.1) |
2.47 |
1.04 | |
|
|
|
CH3 |
I |
|
6.5 (±0.3) |
4.8 (±0.8) |
14 (±2) |
1.99 |
0.84 | |
|
|
|
H |
I |
|
0.13 (±0.10) |
0.008 (±0.001) |
5.6 (±1.1) |
2.87 |
1.21 | |
|
|
|
CH3 |
H |
|
1.0 (±0.1) |
1.0 (±0.1) |
>82 |
1.69 |
0.71 | |
|
|
|
CH3 |
H |
|
78 (±4) |
57 (±3) |
48 (±5) |
0.28 |
0.12 | |
|
|
|
H |
H |
|
2.4 (±0.2) |
1.7 (±0.3) |
>84 |
3.78 |
1.59 | |
[a] Comments: [i] Krelative change in fluorescence intensity of pyrene‐labelled actin over time relative to the same change induced by jasplakinolide (both in the linear part of the curve after applying linear fit); [ii] data rounded to meaningful digits.
In silico calculated parameters for geodiamolide H and analogues:[a]
|
Entry |
Compound |
In cellulo |
In vitro |
In silico |
| |||||
|
|
|
|
|
|
|
|
Binding |
ADME | ||
|
|
|
R |
X |
E/Z |
Hrel [i] |
Krel [ii] |
docking score[iii] |
QPlogS[iv] |
QPPMDCK[v] | |
|
|
|
|
|
|
1 |
1 |
−6.13 |
−6.08 |
329.80 | |
|
|
|
CH3 |
I |
|
0.2 |
1.04 |
−6.21 |
−5.11 |
189.31 | |
|
|
|
CH3 |
I |
|
0.01 |
0.84 |
−4.31 |
−4.26 |
171.01 | |
|
|
|
H |
I |
|
0.62 |
1.21 |
−5.82 |
−5.88 |
227.66 | |
|
|
|
CH3 |
H |
|
0.08 |
0.71 |
−5.50 |
−4.11 |
125.46 | |
|
|
|
CH3 |
H |
|
0.001 |
0.12 |
−5.20 |
−4.05 |
63.55 | |
|
|
|
H |
H |
|
0.03 |
1.59 |
−7.12 |
−3.33 |
58.47 | |
[a] Comments: [i] H‐relative cytotoxicity to jasplakinolide in HeLa cell line; [ii] K relative change in fluorescence intensity of pyrene‐labelled actin over time relative to the same change induced by jasplakinolide (both in the linear part of the curve after applying linear fit); [iii] Docking score units are kcal/mol; [iv] Predicted aqueous solubility – log S; S (in mol dm−3); [v] predicted apparent MDCK cell permeability (in nm/sec).
Figure 4The binding site of cyclodepsipeptides on F‐actin and SAR; (a) Geodiamolide H docked in the binding cleft of F‐actin (PDB 6T23), amino acids on the surface of the protein are marked according to hydrophobicity;[, ] (b) Compiled SAR features of geodiamolides.